Despite poor growth, the company's P/S ratio exceeds industry peers, raising concerns. Investors hoping for a business turnaround may face disappointment if the P/S aligns with negative growth rates. Without significant medium-term improvements, the share price may seem overvalued.
莱美药业股票讨论区
暂无评论